How soon should patients be eligible for differentiated service delivery models for antiretroviral treatment? Evidence from Zambia

Lise Jamieson^{1,2}, Sydney Rosen^{1,3}, Bevis Phiri⁴, Anna Grimsrud⁵, Muya Mwansa⁶, Hilda Shakwelele⁴, Prudence Haimbe⁴, Mpande M Mwenechanya⁷, Priscilla Lumano Mulenga⁶, Brooke E Nichols^{1,2,3*}

¹Health Economics and Epidemiology Research Office (HE²RO), Department of Internal Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa

²Department of Medical Microbiology, Amsterdam University Medical Centre, Amsterdam, the Netherlands

³Department of Global Health, Boston University School of Public Health, Boston, MA, USA

⁴Clinton Health Access Initiative, Lusaka, Zambia

⁵International AIDS Society, Cape Town, South Africa

⁶Ministry of Health, Lusaka, Zambia

⁷The Centre for Infectious Disease Research in Zambia, Lusaka, Zambia

*Corresponding author: Brooke Nichols (brooken@bu.edu)

Word count: 2,556

Abstract

Word count: 321

Background: Most differentiated service delivery (DSD) models for HIV treatment, which are intended to improve ART programme outcomes, require that a patient have spent ≥ 6 or ≥ 12 months on antiretroviral treatment (ART) for eligibility. Attrition from ART programmes, however, is highest among those newly initiated and thus ineligible for DSD models. Because some patients are enrolled “early,” prior to 6 or 12 months on ART, we were able to evaluate loss to follow-up among patients in Zambia enrolled in DSD models after differing intervals on ART.

Methods: Data were extracted from electronic medical records of patients (≥ 15 years) enrolled in DSD models from October 2019-March 2020. We compared 12-month loss to follow-up (LTFU), defined as “lost to follow-up,” “inactive,” or “stopped ART” at 9-15 months after DSD enrolment, among patients enrolled in six DSD models after < 6 months, 6-12 months, and ≥ 12 months on ART, with those enrolled with < 6 or < 12 months on ART termed “early enrollers and those enrolled with ≥ 12 months termed “established.” We adjusted for age, sex, urban/rural status, and duration of ART dispensing.

Results: Of 88,556 patients enrolled in a DSD model, 4% ($n=3,143$) and 8% ($n=6,714$) had initiated ART < 6 months or 6-12 months before DSD entry, respectively. Early enrollers were less likely to be LTFU at 12 months than established patients (adjusted risk ratio (aRR) [95% confidence interval] for < 6 months on ART 0.72 [0.62-0.83]; aRR 0.74 [0.67-0.82] for 6-12 months on ART) for almost all DSD models and dispensing durations. A limitation of the analysis is that early enrollers may have been selected for DSD participation due to providers’ expectations about future retention.

Conclusions: Patients enrolled in DSD models in Zambia after less than a year on ART were more likely to be retained in care 12 months later than were patients established on ART at DSD enrollment. Offering enrollment to at least some newly-initiating ART patients may improve ART programme outcomes.

Introduction

A critical step toward achieving universal coverage of antiretroviral therapy (ART) for HIV is to support lifelong patient retention in ART programmes. Data from sub-Saharan Africa (SSA), where some 70% of the world's ART patients reside, continue to indicate insufficient retention on ART (1), with about a fifth of all patients lost to care by 5 years after treatment initiation (2). A patient's first six months and first year after initiation are the highest risk period: a Zambian study showed rates of loss to follow-up to be four-fold higher in the first six months of ART treatment compared to the period between 6 months and 3.5 years thereafter (3).

Since 2016, the World Health Organization (WHO) has recommended differentiated service delivery (DSD) for HIV treatment (4). DSD models increase access and remove barriers to care by adjusting the cadre of provider, location of service delivery, frequency of interactions with the healthcare system, and/or types of services offered to support long-term retention of people established on HIV treatment (5). A recent systematic review reporting on outcomes of patients in DSD models in SSA found that retention in care of those in DSD models was generally within 5% of that for conventional care (6). In Zambia, several DSD models have shown to have similar rates of retention as conventional care 12 months after DSD model entry (7,8). The INTERVAL trial, a cluster-randomized, non-inferiority trial conducted in Malawi and Zambia, found that 6-month ART dispensing was non-inferior in terms of 12-month retention, compared to standard of care (8). DSD models have consistently been found to save substantial time and money for patients themselves, and satisfaction with the models among both providers and patients has been high (8–10).

A major limitation of DSD models to date has been eligibility criteria that limit model enrollment to patients on the standard first-line ART regimen who are “stable” or “established on treatment,” defined as having been on ART for at least 6 or 12 months and having demonstrated viral suppression (8,11–13). Until April 2021, the WHO's definition of “established” included at least 12 months of ART experience; new guidelines require at least 6 months on ART for DSD model eligibility (14). Patients who are newly initiated on ART are thus systematically excluded from DSD models and from the benefits they offer. In the previously cited INTERVAL trial in Malawi and Zambia, 10% of all patients were excluded due to having initiated ART less than 6 months prior (15). For patients not eligible for DSD models, guidelines typically require frequent visits to the healthcare facility and medication dispensing intervals of no more than 3 months (16).

Despite existing guidelines limiting DSD eligibility based on time on ART, in practice patients who do not meet guideline-recommended criteria are often enrolled in DSD models, due to provider decision or error or patient request. To begin to understand how such patients fare when participating in DSD models for those established on treatment, we analyzed routinely collected medical record data from Zambia to compare rates of retention among patients enrolled into DSD models earlier than prevailing guidelines allowed with retention among those who met all eligibility criteria.

Methods

Study population and outcomes

Data were retrospectively extracted in March 2021 from SmartCare, Zambia's national electronic medical record system (17). We extracted data for all adults (aged 15 years or older) reported to have

enrolled in a DSD model between October 2019 and March 2020 at any of 563 health facilities across all 10 provinces. Zambian policy guidelines for this period required patients to be stable on ART before they are considered for DSD enrolment, with stability defined in the 2018 DSD framework guidelines (11,12) as on ART for at least 12 months.

We categorized patients into three groups defined by how long they had been on ART at the time of DSD model entry: (1) 12 months or longer; (2) 6-12 months; and (3) <6 months. We refer to the first group (≥ 12 months) as “established enrollers” and the two latter groups as “early enrollers”. Patients on second-line ART (defined as those dispensed protease inhibitors such as lopinavir or atazanavir) were excluded from this analysis, as they are already known to be at high risk of attrition (18,19).

Outcomes of patients were assessed as of 31 December 2020. Our primary outcome was loss to follow-up at 12 months after DSD enrollment, defined as a patient being reported as “lost to follow-up,” “inactive,” or “stopped ART” in the Smartcare database between 9 and 15 months after DSD enrollment. (“Inactive” is defined as having missed a scheduled visit by more than 30 days.) Rates of loss to follow-up were calculated by time on ART at DSD entry and stratified by DSD model type and medication dispensing duration. DSD models, which bore multiple names in the SmartCare database, were grouped into categories as follows: 1) adherence groups (community adherence groups, rural/urban adherence groups); 2) extended clinic hours (DSD models designed for clinic access before/after hours or weekends, including scholar models); 3) fast-track (procedures to accelerate dispensing at clinics); 4) home ART delivery; 5) multi-month dispensing (MMD); and 6) community pick-up point (central dispensing units, community retail pharmacies, community ART distribution points, health posts, mobile ART distribution models) (Table 1).

Table 1. Differentiated service delivery (DSD) models for HIV treatment in use in Zambia during the study period

Category	Model(s) in category	Description
Adherence groups	Community adherence groups	Patient groups, consisting of ± 6 members, meeting at an agreed time every 1-3 months. The groups are managed by the patients themselves, and usually meet outside of the health facility. Members collect ART at clinical appointments for other members in a rotating fashion (7).
	Rural and urban adherence groups/clubs	Patient groups, consisting of 20-30 members, meeting at an agreed time every 2-3 months. Groups are often facilitated by the same health care worker or facility-based volunteer, also providing pre-packaged ART (7).
Extended clinic hours	Before/after-hours models, weekend models, scholar models	These models allow patients to have a clinical visit and collect their ART outside the conventional operation times at the facility (early mornings, evenings and over weekends). These are beneficial to patients with competing priorities (e.g. school or employment).
Fast-track	Fast-track	A model that typically involves a separate, shorter queue to dispense ART to stable patients, allowing for a quick patient visit when a clinical visit is not required (20)
Home ART delivery	Home ART delivery	Trained community health workers (CHWs) linked to facilities conduct home visits to deliver ART, conduct health screening, monitor adherence, and refer patients as required (7).
Multi-month dispensing	Multi-month dispensing	Facility-based model in which the primary goal is to dispense medications for more than one month (usually 6 months). Dispensing is typically done during a clinical facility-based visit.
Community pick-up point	Central dispensing units	A centralized model for ART distribution, where medication is packed at a centrally located hub and distributed to patients at multiple approved pick-up points. Clinic visits occur every 6 months at the health facility (11).
	Community ART distribution points,	ART refills are provided to patients outside of health facilities, e.g. schools, churches, community centres, community retail pharmacies and health posts (11).

Category	Model(s) in category	Description
	community retail pharmacies, health posts	
	Mobile ART distribution models	A clinical outreach team linked to a facility does 3-monthly clinical assessments at community distribution points. This model is usually used for hard-to-reach areas (11).

Statistical analysis

We described the demographics of our study population using basic descriptive statistics. We compared risk of loss to follow-up among early enrollers to LTFU among established enrollers. Wilson's score interval is used to calculate 95% confidence intervals around proportions. We used a log-binomial regression to calculate risk ratios for loss to follow-up, adjusting for age, sex, urban/rural status and where applicable, DSD model type and dispensing duration.

Ethics

This study protocol was approved by ERES Converge IRB (Zambia), protocol number 2019-Sep-030, the Human Research Ethics Committee (Medical) of the University of Witwatersrand, protocol number M190453, and the Boston University IRB, protocol number H-38823.

Results

Model enrollment

Of the 88,556 adults reported in SmartCare to have been enrolled in DSD models during the study period who were on first line ART and had no known viral failure, 89% (n=78,699) had been on ART for 12 months or more at the time of DSD model entry, 8% (n=6,714) had been on ART for 6-12 months at DSD entry, and 4% (n=3,143) had been on ART for <6 months at DSD entry (Table 2). More patients who enrolled in DSD models after <6 months (43%, n=1,333) or 6-12 months (38%, n=2,549) on ART were under 35 years of age than those enrolled after >12 months (19%, n=15,567). There were no other important differences by group (Appendix Figure S1).

Most patients in the cohort were enrolled in the multi-month dispensing (49%, n=43,257) or fast-track (38%, n=34,071) models, with small proportions in the other models: 7% (n=5,989) in community pick-up points, 5% (n=4,185) in adherence groups, 1% (n=519) in extended clinic hour models, and 1% (n=535) in home ART delivery models (Table 2). Established enrollers were more likely to participate in the fast track model, while early enrollers were more likely to be offered multi-month dispensing.

Table 2. Demographics of patients enrolled in differentiated service delivery models

Characteristic		Total (N=88,556)	≥12 months (N=78,699)	6-12 months (N=6,714)	<6 months (N=3,143)
Sex	Female	64% (56,863)	65% (50,830)	61% (4,082)	62% (1,951)
	Male	36% (31,693)	35% (27,869)	39% (2,632)	38% (1,192)
Age group (years)	15-24	4% (3,601)	3% (2,695)	9% (572)	11% (334)
	25-34	18% (15,848)	16% (12,872)	29% (1,977)	32% (999)
	35-49	52% (45,642)	52% (41,254)	46% (3,056)	42% (1,332)
	50+	26% (23,465)	28% (21,878)	17% (1,109)	15% (478)
Urban/rural	Rural	22% (19,496)	21% (16,862)	26% (1,747)	28% (887)
	Urban	78% (69,058)	79% (61,835)	74% (4,967)	72% (2,256)
	Adherence groups	5% (4,185)	5% (3,974)	2% (147)	2% (64)

Characteristic		Total (N=88,556)	≥12 months (N=78,699)	6-12 months (N=6,714)	<6 months (N=3,143)
Differentiated service delivery model	Extended clinic hours	1% (519)	1% (417)	1% (58)	1% (44)
	Fast-track	38% (34,071)	41% (31,895)	23% (1,576)	19% (600)
	Home ART delivery	1% (535)	1% (396)	1% (70)	2% (69)
	Multi-month dispensing	49% (43,257)	47% (36,800)	66% (4,442)	64% (2,015)
	Community pick-up point	7% (5,989)	7% (5,217)	6% (421)	11% (351)
Outcome at 12 months after DSD entry	Died	<1% (207)	<1% (181)	<1% (11)	<1% (15)
	Lost to follow-up	7% (5,965)	7% (5,375)	6% (402)	6% (188)
	Retained in care	93% (82,384)	93% (73,143)	94% (6,301)	94% (2,940)

Outcomes

Patients who were newly initiated onto ART at DSD entry had a slightly lower rate of loss to follow-up (<6 months on ART: 6.0% [95% confidence interval (CI) 5.4%-6.6%]; and 6-12 months on ART: 6.0% [5.2%-6.9%]) than did those who were on ART >12 months at DSD entry (6.8% [6.7%-7.0%]) (Table 3).

Early enrollers experienced similar or lower loss to follow-up rates than established enrollers across nearly all models of care (Table 3). The exception was fast-track: patients on ART for <6 months enrolled in fast-track had a higher rate of loss to follow-up than those on ART >12 months (8.0%; [6.1%-10.4%] vs. 5.0% [4.8%-5.2%], respectively). Across all groups, longer dispensing periods were associated with lower rates of loss to follow-up, ranging between 5.0%-6.0% (4-6 month), 6.0%-8.0% (3 months) and 12.0%-16.0% (<2 months) (Table 3).

Table 3. Proportion of patients lost to follow-up within 12 months after enrollment into a differentiated service delivery (DSD) model, by time on ART at DSD entry (95% confidence interval in round brackets, sample numbers in square brackets)

	>12 months on ART	6-12 months on ART	<6 months on ART
Overall	6.8% (6.7%-7.0%) [5,375/78,699]	6.0% (5.4%-6.6%) [402/6,714]	6.0% (5.2%-6.9%) [188/3,143]
By DSD model			
Adherence groups	6.0% (5.3%-6.8%) [238/3,974]	2.0% (0.7%-5.8%) [3/147]	5.0% (1.8%-13.3%) [3/64]
Extended clinic hours	8.6% (6.3%-11.7%) [36/417]	8.6% (3.7%-18.6%) [5/58]	6.8% (2.3%-18.2%) [3/44]
Fast-track	5.0% (4.8%-5.2%) [1,595/31,895]	5.0% (4.0%-6.2%) [79/1,576]	8.0% (6.1%-10.4%) [48/600]
Home ART delivery	9.3% (6.8%-12.6%) [37/396]	7.1% (3.1%-15.6%) [5/70]	7.2% (3.1%-15.8%) [5/69]
Multi-month dispensing	8.0% (7.7%-8.3%) [2,944/36,800]	6.0% (5.3%-6.7%) [267/4,442]	6.0% (5.0%-7.1%) [121/2,015]
Community pick-up point	8.0% (7.3%-8.8%) [417/5,217]	6.0% (4.1%-8.7%) [25/421]	5.0% (3.2%-7.8%) [18/351]
By months ART dispensed			
<2 months	16.0% (14.9%-17.2%) [610/3,812]	14.0% (11.4%-17.1%) [78/556]	12.0% (8.7%-16.4%) [33/273]
3 months	8.0% (7.5%-8.5%) [949/11,863]	7.0% (5.8%-8.4%) [110/1,566]	6.0% (4.6%-7.7%) [54/904]
4-6 months	6.0% (5.8%-6.2%) [3,781/63,018]	5.0% (4.4%-5.7%) [230/4,592]	5.0% (4.1%-6.1%) [98/1,966]

In the adjusted analysis, early enrollers in all DSD model types and dispensing durations, except for fast-track, were 26-28% less likely to be lost to follow-up than established enrollers (adjusted risk ratio (aRR) 0.72 [0.63-0.82] for <6 months on ART and 0.74 [0.67-0.82] for 6-12 months on ART) (Figure 1).

Fast-track patients with <6 months of ART at DSD entry had slightly higher adjusted risk of loss to follow-up than did established patients (aRR 1.09 [0.81-1.47]) (Figure 1). We also conducted an age-stratified analysis (Appendix Figure S2) and a sub-analysis restricted to facilities with a higher proportion of DSD patients enrolled with <6 months ART (Appendix Figure S3). The age-stratified analysis had similar results as the main analysis, with those in each age group enrolled into DSD after being newly initiated on ART being less likely to be lost to follow-up than those on ART >12 months at DSD enrolment in the same age group. The effect appears less pronounced in older age groups, however (Appendix Figure S2). The sub-analysis found that in facilities where a larger proportion of all DSD patients enrolled in DSD models early, with <12 months on ART, the early enrollers still performed better with respect to loss to follow-up than did established enrollers (Appendix Figure S3).

Figure 1. Relative risk of loss to follow-up within 12 months of DSD enrollment for patients who enrolled into DSD models after <6 and 6-12 months of ART (reference group: patients on ART for >12 months at DSD entry; analysis adjusted for age, sex, urban/rural status and number of months dispensed (for DSD stratified analysis) and DSD model (for months dispensed stratified analysis))

Discussion

Throughout sub-Saharan Africa, DSD model eligibility criteria require that patients be on ART for a minimum of 6 months (and in some countries a minimum of 12 months) prior to DSD model enrollment. We present novel data from Zambia highlighting good outcomes for newly initiated ART patients (those with less than 6 or less than 12 months' ART experience) in DSD models.

Our data begin to fill in a gap in the evidence base on DSD models. Because few if any countries permit DSD model enrollment for new initiators, little evidence on their experience in DSD models has been available until now. To date, most reports on DSD outcomes have been limited to people who have spent a significant amount of time on ART prior to DSD model enrollment. In the previously mentioned INTERVAL trial, for example, participants had been on ART for a median of roughly 5 years at DSD model entry, while patients in a trial of multi-month dispensing in adherence clubs in South Africa had a median duration on ART of 7.3 years at baseline (21).

While ART patients in Zambia have historically dropped out of treatment at high rates in the first few months after ART initiation (3), in our DSD patient population this was less likely to be the case. Our results justify the recent revision of WHO guidelines reducing the definition of "established" to include at least 6 months on ART, rather than at least 12 months (14). These findings should provide reassurance and evidence to countries that have expanded eligibility as they scale up DSD models (22,23), particularly as a result of the COVID-19 pandemic, that earlier referral to DSD is possible without compromising patient care. Even if many (or most) of the patients in our "early enrollment" sample were selected deliberately because they were considered at low loss to follow-up risk, our results also demonstrate that early eligibility for DSD models should be considered for at least some patients before they reach 6 months on ART.

Loss to follow up during the 12-month observation period (12 months after DSD model entry) for all three groups of patients (<6 months, 6-12 months, and >12 months) averaged 5-8% for all six categories of DSD models studied. We did not observe any programmatically important differences by model or ART experience prior to model enrollment. Where a programmatically important difference did arise, in contrast, was in dispensing intervals. Regardless of how long a patient had been on ART at DSD model enrollment, patients who received ≤ 2 months of medications at a time were substantially more likely to be lost to follow up by the end of the 12-month period than patients who received either 3 months or 4-6 months of medications. This likely reflects providers' assessments of patients' ability to remain on treatment. Those regarded as being at higher risk of attrition are asked to come to the clinic for medication refills more often, so that they can be monitored and supported more closely. Ironically, difficulty in accessing the clinic may be the very reason that some patients are at high risk of attrition. For these patients, insisting on shorter refill durations may simply exacerbate whatever challenges they face.

There were several limitations to our analysis. First, as noted above, we assume that patients with < 6 months on ART in our sample were not offered DSD model enrollment at random. If providers made accurate guesses about individual patients' risks of attrition, patients in our "early enrollment" cohorts could over-represent patients thought to have low attrition risk. To achieve the results we found, providers would have had to make these accurate guesses correctly at multiple sites across the entire country. If this is the case, our data suggest that the healthcare workers responsible for enrolling patients into DSD models can successfully identify those who will do well with early enrollment. At the same time, if the early enrollers in our data set do comprise patients at lower risk of LTFU, then our

results likely underestimate the true rate of LTFU that would occur if early DSD enrollment were to be broadly available, without the benefit of provider selection. Potentially offsetting this effect, however, is the survivor bias reflected in our cohort of patients who enrolled in DSD models ≥ 12 months after ART initiation. Since we found that those enrolled ≥ 12 months' post ART initiation had a substantially *higher* rate of LTFU than those enrolled < 12 months, we believe that the protective effect of early DSD enrollment is likely to be a true effect and probably not fully offset by the potential provider selection bias discussed above.

A second limitation is that our data set included only patients reported in the electronic medical record system to have enrolled in a DSD model. It is possible that some patients not in DSD models may be recorded as enrolled, and some who were enrolled may have been missed. Third, we could not compare outcomes for newly initiated ART patients in conventional, facility-based care to those on DSD models within the same facilities. A potential concern of bias would be that if facilities with better-than-average retention in care were also more likely to allow early DSD model enrollment, our results may reflect differences in facility quality, as well as enrollment timing. An analysis restricted to facilities with $> 10\%$ early DSD enrolment showed an even lower risk of loss to follow-up within patients enrolled early into DSD models, however, compared to patients with > 12 months of ART at DSD entry.

Despite these limitations, our analysis demonstrates that patients on ART for less than 6 months who are enrolled in existing DSD models can be successfully retained in care and may even fare better than those left in conventional care. It is likely that not all patients are ready for less intensive DSD models in their first half-year or year on treatment, but some clearly are. Since DSD models have been shown to be beneficial to patients and in some cases to providers, offering enrollment to newly-initiating ART patients may improve ART programs in general. Future research should look more closely at which patients can be enrolled early and which models of care serve these patients best.

References

1. UNAIDS AIDSinfo: People living with HIV receiving ART [Internet]. 2020 [cited 2021 Jun 15]. Available from: <https://aidsinfo.unaids.org/>
2. Haas AD, Zaniewski E, Anderegg N, Ford N, Fox MP, Vinikoor M, et al. Retention and mortality on antiretroviral therapy in sub-Saharan Africa: collaborative analyses of HIV treatment programmes. *J Intern AIDS Soc*. 2018 Feb;21(2):e25084.
3. Schöni-Affolter F, Keiser O, Mwango A, Stringer J, Ledergerber B, Mulenga L, et al. Estimating Loss to Follow-Up in HIV-Infected Patients on Antiretroviral Therapy: The Effect of the Competing Risk of Death in Zambia and Switzerland. Myer L, editor. *PLoS ONE*. 2011 Dec 19;6(12):e27919.
4. World Health Organization. Guidelines on HIV self-testing and partner notification, supplement to consolidated guidelines on HIV testing services [Internet]. 2016 [cited 2020 Nov 18]. Available from: <https://www.who.int/hiv/pub/vct/hiv-self-testing-guidelines/en/>
5. Duncombe C, Rosenblum S, Hellmann N, Holmes C, Wilkinson L, Biot M, et al. Reframing HIV care: putting people at the centre of antiretroviral delivery. *Trop Med Int Health*. 2015 Apr;20(4):430–47.
6. Long L, Kuchukhidze S, Pascoe S, Nichols BE, Fox MP, Cele R, et al. Retention in care and viral suppression in differentiated service delivery models for HIV treatment delivery in sub-Saharan Africa: a rapid systematic review. *J Intern AIDS Soc* [Internet]. 2020 Nov [cited 2021 May 14];23(11). Available from: <https://onlinelibrary.wiley.com/doi/10.1002/jia2.25640>
7. Nichols BE, Cele R, Jamieson L, Long LC, Siwale Z, Banda P, et al. Community-based delivery of HIV treatment in Zambia: costs and outcomes. *AIDS*. 2021 Feb 2;35(2):299–306.
8. Hoffman RM, Moyo C, Balakasi KT, Siwale Z, Hubbard J, Bardon A, et al. Multimonth dispensing of up to 6 months of antiretroviral therapy in Malawi and Zambia (INTERVAL): a cluster-randomised, non-blinded, non-inferiority trial. *The Lancet Global Health*. 2021 May;9(5):e628–38.
9. Nichols BE, Cele R, Lekodeba N, Tukei B, Ngorima-Mabhena N, Tiam A, et al. Economic evaluation of differentiated service delivery models for HIV treatment in Lesotho: costs to providers and patients. *J Intern AIDS Soc* [Internet]. 2021 Apr [cited 2021 Jun 1];24(4). Available from: <https://onlinelibrary.wiley.com/doi/10.1002/jia2.25692>
10. Guthrie T, Muheki C, Greener R, Kanoowe S, Lagony S, Miot J, et al. Costs and outcomes of differentiated ART service delivery in Uganda: summary of findings. [Internet]. 2020. Available from: <https://sites.bu.edu/ambit/files/2021/02/Uganda-EQUIP-Brief-ART-DSDM-cost-outcomes-FINAL-2020.08.24.pdf>
11. Ministry of Health. Zambia Differentiated Service Delivery Framework. 2018.
12. Republic of Zambia. Ministry of Health. Zambia Consolidated Guidelines for Treatment and Prevention of HIV Infection. 2018.
13. Republic of Zambia. Ministry of Health. Zambia Consolidated Guidelines for Treatment and Prevention of HIV Infection. 2020.

14. World Health Organization. Updated recommendations on service delivery for the treatment and care of people living with HIV. [Internet]. 2021 Apr. Available from: <https://apps.who.int/iris/rest/bitstreams/1344311/retrieve>
15. Hoffman RM, Balakasi K, Bardon AR, Siwale Z, Hubbard J, Kakwesa G, et al. Eligibility for differentiated models of HIV treatment service delivery: an estimate from Malawi and Zambia. *AIDS*. 2020 Mar 1;34(3):475–9.
16. Rosen S, Grimsrud A, Ehrenkranz P, Katz I. Models of service delivery for optimizing a patient's first six months on antiretroviral therapy for HIV: an applied research agenda. *Gates Open Res*. 2020;4:116.
17. Gumede-Moyo S, Todd J, Bond V, Mee P, Filteau S. A qualitative inquiry into implementing an electronic health record system (SmartCare) for prevention of mother-to-child transmission data in Zambia: a retrospective study. *BMJ Open*. 2019 Sep;9(9):e030428.
18. Wandeler G, Keiser O, Mulenga L, Hoffmann CJ, Wood R, Chaweza T, et al. Tenofovir in Second-Line ART in Zambia and South Africa: Collaborative Analysis of Cohort Studies. *JAIDS Journal of Acquired Immune Deficiency Syndromes*. 2012 Sep 1;61(1):41–8.
19. Kebede HK, Mwanri L, Ward P, Gesesew HA. Predictors of lost to follow up from antiretroviral therapy among adults in sub-Saharan Africa: a systematic review and meta-analysis. *Infect Dis Poverty*. 2021 Dec;10(1):33.
20. Huber A, Pascoe S, Nichols B, Long L, Kuchukhidze S, Phiri B, et al. Differentiated Service Delivery Models for HIV Treatment in Malawi, South Africa, and Zambia: A Landscape Analysis. *Glob Health Sci Pract*. 2021 May 10;ghsp;GHSP-D-20-00532v1.
21. Cassidy T, Grimsrud A, Keene C, Lebelo K, Hayes H, Orrell C, et al. Twenty-four-month outcomes from a cluster-randomized controlled trial of extending antiretroviral therapy refills in ART adherence clubs. *J Int AIDS Soc*. 2020 Dec;23(12):e25649.
22. Grimsrud A, Wilkinson L. Acceleration of differentiated service delivery for HIV treatment in sub-Saharan Africa during COVID-19. *J Int AIDS Soc* [Internet]. 2021 Jun [cited 2021 Jul 12];24(6). Available from: <https://onlinelibrary.wiley.com/doi/10.1002/jia2.25704>
23. Time on ART before eligibility for DSD for HIV treatment. Differentiated Service Delivery. [Internet]. 2020. Available from: <https://differentiatedservicedelivery.org/Portals/0/adam/Content/jcdklT8RzEqirRdIckAjbQ/File/1-Time%20to%20DSD%20Eligibility%20D5.pdf>